Maribavir Patent Expiration
Maribavir is Used for treating post-transplant cytomegalovirus (CMV) infection/disease refractory to other antiviral treatments in stem cell, kidney, or liver transplant recipients. It was first introduced by Takeda Pharmaceuticals Usa Inc
Maribavir Patents
Given below is the list of patents protecting Maribavir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Livtencity | US12295940 | Viral inhibitors, the synthesis thereof, and intermediates thereto | Oct 11, 2043 | Takeda Pharms Usa |
| Livtencity | US12527771 | Viral Inhibitors, The Synthesis Thereof, And Intermediates Thereto | Oct 11, 2043 | Takeda Pharms Usa |
| Livtencity | US12213989 | Use of maribavir in treatment regimens | Nov 18, 2042 | Takeda Pharms Usa |
| Livtencity | US12433907 | Use Of Maribavir In Treatment Regimens | Nov 18, 2042 | Takeda Pharms Usa |
| Livtencity | US12447170 | Use Of Maribavir In Treatment Regimens | Nov 18, 2042 | Takeda Pharms Usa |
| Livtencity | US11684632 | Maribavir isomers, compositions, methods of making and methods of using | Jan 04, 2032 | Takeda Pharms Usa |
| Livtencity | US12447169 | Maribavir Isomers, Compositions, Methods Of Making And Methods Of Using | Oct 27, 2031 | Takeda Pharms Usa |
| Livtencity | US12661368 | Maribavir Isomers, Compositions, Methods Of Making And Methods Of Using | Oct 27, 2031 | Takeda Pharms Usa |
Maribavir's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Maribavir:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections | Takeda | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) | Takeda | NA |
RECRUITING
(May 1, 2026)
| PHASE3 |
| Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT | Ruijin Hospital | NA |
RECRUITING
(Mar 1, 2026)
| PHASE3 |